CD99 dual behavior has been reported to be associated with tumor progression in Ewing sarcoma and acute lymphoblastic leukemia [21], as tumor suppressor in osteosarcoma [22], and in Hodgkin’s lymphoma [23], which may be attributed to differential preponderance of CD99 isoforms. Here, CD99 is linked to osteosarcoma.